Craig M Kessler

List of Publications by Year
in descending order

Source: https://exaly.com/author-pdf/7467894/publications.pdf

Version: 2024-02-01

80 papers	3,598 citations	201674 27 h-index	133252 59 g-index
86 all docs	86 docs citations	86 times ranked	3217 citing authors

#	Article	IF	Citations
1	Long-Term, Low-Intensity Warfarin Therapy for the Prevention of Recurrent Venous Thromboembolism. New England Journal of Medicine, 2003, 348, 1425-1434.	27.0	771
2	International recommendations on the diagnosis and treatment of patients with acquired hemophilia A. Haematologica, 2009, 94, 566-575.	3.5	362
3	Thrombocytopenia following Pfizer and Moderna <scp>SARSâ€CoV</scp>â€2 vaccination. American Journal of Hematology, 2021, 96, 534-537.	4.1	331
4	Reversal of Warfarin-Induced Excessive Anticoagulation with Recombinant Human Factor VIIa Concentrate. Annals of Internal Medicine, 2002, 137, 884.	3.9	244
5	Treatment of von Willebrand disease with a high-purity factor VIII/von Willebrand factor concentrate: a prospective, multicenter study. Blood, 2002, 99, 450-456.	1.4	188
6	International recommendations on the diagnosis and treatment of acquired hemophilia A. Haematologica, 2020, 105, 1791-1801.	3.5	182
7	Consensus recommendations for the diagnosis and treatment of acquired hemophilia A. BMC Research Notes, 2010, 3, 161.	1.4	149
8	Pegylated interferon alfa-2a for polycythemia vera or essential thrombocythemia resistant or intolerant to hydroxyurea. Blood, 2019, 134, 1498-1509.	1.4	123
9	A randomized trial of avatrombopag, an investigational thrombopoietin-receptor agonist, in persistent and chronic immune thrombocytopenia. Blood, 2014, 123, 3887-3894.	1.4	112
10	Acquired haemophilia: an overview for clinical practice. European Journal of Haematology, 2015, 95, 36-44.	2.2	82
11	The effect of emicizumab prophylaxis on healthâ€related outcomes in persons with haemophilia A with inhibitors: HAVEN 1 Study. Haemophilia, 2019, 25, 33-44.	2.1	63
12	Factor VIII: Long-established role in haemophilia A and emerging evidence beyond haemostasis. Blood Reviews, 2019, 35, 43-50.	5.7	57
13	New Perspectives in Hemophilia Treatment. Hematology American Society of Hematology Education Program, 2005, 2005, 429-435.	2.5	49
14	The Link Between Cancer and Venous Thromboembolism. American Journal of Clinical Oncology: Cancer Clinical Trials, 2009, 32, S3-S7.	1.3	45
15	A randomized phase 3 trial of interferon-Î± vs hydroxyurea in polycythemia vera and essential thrombocythemia. Blood, 2022, 139, 2931-2941.	1.4	45
16	Reversal of low-molecular-weight heparin-induced bleeding in patients with pre-existing hypercoagulable states with human recombinant activated factor VII concentrate. American Journal of Hematology, 2006, 81, 582-589.	4.1	43
17	Assessment of acquired hemophilia patient demographics in the United States. Blood Coagulation and Fibrinolysis, 2016, 27, 761-769.	1.0	39
18	Results of the Myeloproliferative Neoplasms - Research Consortium (MPN-RC) 112 Randomized Trial of Pegylated Interferon Alfa-2a (PEG) Versus Hydroxyurea (HU) Therapy for the Treatment of High Risk Polycythemia Vera (PV) and High Risk Essential Thrombocythemia (ET). Blood, 2018, 132, 577-577.	1.4	39

#	Article	IF	Citations
19	Assessments of pain, functional impairment, anxiety, and depression in US adults with hemophilia across patientâ€reported outcome instruments in the Pain, Functional Impairment, and Quality of Life (Pâ€FiQ) study. European Journal of Haematology, 2018, 100, 5-13.	2.2	37
20	Effect of Anticoagulant Therapy for 6 Weeks vs 3 Months on Recurrence and Bleeding Events in Patients Younger Than 21 Years of Age With Provoked Venous Thromboembolism. JAMA - Journal of the American Medical Association, 2022, 327, 129.	7.4	37
21	Recombinant factor VIIa in the management of postpartum bleeds: an audit of clinical use. Acta Obstetricia Et Gynecologica Scandinavica, 2006, 85, 1239-1247.	2.8	35
22	New products for managing inhibitors to coagulation factors: a focus on recombinant factor VIIa concentrate. Current Opinion in Hematology, 2000, 7, 408-413.	2.5	34
23	Longâ€term risk of recurrence in patients with a first unprovoked venous thromboembolism managed according to dâ€dimer results; A cohort study. Journal of Thrombosis and Haemostasis, 2019, 17, 1144-1152.	3.8	34
24	Coagulation factor IX: Successful surgical experience with a purified factor IX concentrate. American Journal of Hematology, 1992, 40, 210-215.	4.1	33
25	Recent developments in topical thrombins. Thrombosis and Haemostasis, 2009, 102, 15-24.	3.4	33
26	Bleeding and safety outcomes in persons with haemophilia A without inhibitors: Results from a prospective nonâ€interventional study in a realâ€world setting. Haemophilia, 2019, 25, 213-220.	2.1	31
27	The pharmacokinetic diversity of two von Willebrand factor (VWF)/ factor VIII (FVIII) concentrates in subjects with congenital von Willebrand disease. Thrombosis and Haemostasis, 2011, 106, 279-288.	3.4	30
28	Impact of hemophilia B on quality of life in affected men, women, and caregiversâ€"Assessment of patientâ€reported outcomes in the Bâ€<scp>HERO</scp>â€s study. European Journal of Haematology, 2018, 100, 592-602.	2.2	30
29	Internal consistency and item-total correlation of patient-reported outcome instruments and hemophilia joint health score v2.1 in US adult people with hemophilia: results from the Pain, Functional Impairment, and Quality of life (P-FiQ) study. Patient Preference and Adherence, 2017, Volume 11, 1831-1839.	1.8	27
30	Management of <scp>US</scp> men, women, and children with hemophilia and methods and demographics of the Bridging Hemophilia B Experiences, Results and Opportunities into Solutions (Bâ€<scp>HERO</scp>â€s) study. European Journal of Haematology, 2017, 98, 5-17.	2.2	25
31	Clinical evaluation of bleeds and response to haemostatic treatment in patients with acquired haemophilia: A global expert consensus statement. Haemophilia, 2019, 25, 969-978.	2.1	24
32	Haemorrhagic complications of thrombocytopenia and oral anticoagulation: is there a role for recombinant activated factor VII?. Intensive Care Medicine, 2002, 28, s228-s234.	8.2	22
33	Recombinant FXIII (rFXIII-A2) Prophylaxis Prevents Bleeding and Allows for Surgery in Patients with Congenital FXIII A-Subunit Deficiency. Thrombosis and Haemostasis, 2018, 118, 451-460.	3.4	22
34	Efficacy and safety of simoctocog alfa (NuwiqÂ®) in patients with severe hemophilia A: a review of clinical trial data from the GENA program. Therapeutic Advances in Hematology, 2019, 10, 204062071985847.	2.5	18
35	Phase II trial of Lestaurtinib, a JAK2 inhibitor, in patients with myelofibrosis. Leukemia and Lymphoma, 2019, 60, 1343-1345.	1.3	17
36	A Phase II Open-Label Study Evaluating Hemostatic Activity, Pharmacokinetics and Safety of Recombinant Porcine Factor VIII (OBI-1) in Hemophilia A Patients with Alloantibody Inhibitors Directed Against Human FVIII.. Blood, 2007, 110, 783-783.	1.4	14

#	Article	IF	Citations
37	A second retrospective database analysis confirms prior findings of apparent increased cardiovascular comorbidities in hemophilia <scp>A</scp> in the <scp>U</scp>nited <scp>S</scp>tates. American Journal of Hematology, 2016, 91, E298-9.	4.1	11
38	Predictors of Remission in Adults with Immune Thrombocytopenia Treated with Romiplostim. Blood, 2018, 132, 735-735.	1.4	11
39	Patientâ€reported outcomes and joint status across subgroups of <scp>US</scp> adults with hemophilia with varying characteristics: Results from the Pain, Functional Impairment, and Quality of Life (Pâ€FiQ) study. European Journal of Haematology, 2018, 100, 14-24.	2.2	10
40	Update on Liver Disease in Hemophilia Patients. Seminars in Hematology, 2006, 43, S13-S17.	3.4	9
41	Feasibility of the Von Willebrand disease PREVENT trial. Thrombosis Research, 2017, 156, 8-13.	1.7	9
42	Sustained Hemostatic Platelet Counts in Adults with Immune Thrombocytopenia (ITP) Following Cessation of Treatment with the TPO Receptor Agonist Romiplostim: Report of 9 Cases,. Blood, 2011, 118, 3281-3281.	1.4	9
43	Antidotes to haemorrhage: recombinant factor VIIa. Best Practice and Research in Clinical Haematology, 2004, 17, 183-197.	1.7	7
44	Treatment of Venous Thromboembolism in Elite Athletes: A Suggested Approach to Individualized Anticoagulation. Seminars in Thrombosis and Hemostasis, 2018, 44, 813-822.	2.7	7
45	Reliability and validity of patientâ€reported outcome instruments in US adults with hemophilia B and caregivers in the Bâ€HEROâ€S study. European Journal of Haematology, 2018, 101, 781-790.	2.2	7
46	The role of total ankle replacement in patients with haemophilia and endâ€stage ankle arthropathy: A review. Haemophilia, 2021, 27, 184-191.	2.1	7
47	The safety of activated eptacog beta in the management of bleeding episodes and perioperative haemostasis in adult and paediatric haemophilia patients with inhibitors. Haemophilia, 2021, 27, 921-931.	2.1	7
48	Emicizumab for the Treatment of Acquired Hemophilia a: A Multicenter US Case Series. Blood, 2021, 138, 496-496.	1.4	7
49	Anticoagulation and Thrombolytic Therapy. Chest, 1989, 95, 245S-256S.	0.8	6
50	Impact on MPN Symptoms and Quality of Life of Front Line Pegylated Interferon Alpha-2a Vs. Hydroxyurea in High Risk Polycythemia Vera and Essential Thrombocythemia: Results of Myeloproliferative Disorders Research Consortium (MPD-RC) 112 Global Phase III Trial. Blood, 2018, 132, 3032-3032.	1.4	6
51	US Experience with Recombinant Factor VIIa (rFVIIa) for Surgery in Acquired Hemophilia (AH): Analysis From the Hemophilia and Thrombosis Research Society (HTRS) Registry. Blood, 2012, 120, 3372-3372.	1.4	5
52	PERSEPT 3: A phase 3 clinical trial to evaluate the haemostatic efficacy of eptacog beta (recombinant) Tj ETQq0 0 0 rgBT /Overlock 10 Tf 2021, 27, 911-920.	2.1	5
53	Acquired Coagulopathy With Immune Checkpoint Inhibitors: An Underrecognized Association Between Inflammation and Coagulation. JTO Clinical and Research Reports, 2020, 1, 100049.	1.1	5
54	Use of objective efficacy criteria for evaluation of von willebrand factor/factor VIII concentrates. Blood Coagulation and Fibrinolysis, 2012, 23, 262-267.	1.0	4

#	Article	IF	Citations
55	Challenges and key lessons from the design and implementation of an international haemophilia registry supported by a pharmaceutical company. Haemophilia, 2020, 26, 966-974.	2.1	4
56	Final Results of Prospective Treatment with Pegylated Interferon Alfa-2a for Patients with Polycythemia Vera and Essential Thrombocythemia in First and Second-Line Settings. Blood, 2019, 134, 2943-2943.	1.4	4
57	Use of Recombinant Factor VIIa (rFVIIa) for Acute Bleeding Episodes in Acquired Hemophilia: Final Analysis From the Hemostasis and Thrombosis Research Society (HTRS) Registry AH Study. Blood, 2012, 120, 4624-4624.	1.4	4
58	A Cross-Sectional Analysis of Cardiovascular Disease in the Hemophilia Population. Blood, 2014, 124, 2836-2836.	1.4	4
59	The Coags Uncomplicated App: Fulfilling Educational Gaps Around Diagnosis and Laboratory Testing of Coagulation Disorders. JMIR Medical Education, 2017, 3, e6.	2.6	3
60	Advances in the treatment of hemophilia. Clinical Advances in Hematology and Oncology, 2008, 6, 184-7.	0.3	3
61	Baby hamster kidney cellâ€“derived recombinant factor VIII: a quarter century of learning and clinical experience. Expert Review of Hematology, 2016, 9, 1151-1164.	2.2	2
62	Publishing in Haemophilia. Haemophilia, 2019, 25, 181-182.	2.1	2
63	Recombinant Factor VIIa (rFVIIa) Is Safe and Effective When Used to Treat Acute Bleeding Episodes and to Prevent Bleeding During Surgery in Patients with Acquired Hemophilia: Updated Assessment From the Hemostasis and Thrombosis Research Society (HTRS) Registry AH Database,. Blood, 2011, 118, 3374-3374.	1.4	2
64	Prevention of Venous Thromboembolism in Hospitalized Medical Patients. Cancer Investigation, 2009, 27, 17-27.	1.3	1
65	The Impact of GM-CSF on Arsenic Trioxide (As2O3, Trisenox) Therapy in Patients with Myelodysplastic Syndrome (MDS): Preliminary Results of a Phase II Study.. Blood, 2006, 108, 4856-4856.	1.4	1
66	The Hemostasis and Thrombosis Research Society (HTRS) Registry Study of Acquired Hemophilia: Assessment of AH Patient Demographics in the US. Blood, 2012, 120, 4625-4625.	1.4	1
67	Impact of Mild to Severe Hemophilia B on Quality of Life Including Pain and Functional Abilities in Affected Men/Women and Caregivers of Affected Boys/Girls: Analysis of Patient Reported Outcomes in the Bridging Hemophilia B Experiences Results and Opportunities into Solutions (B-HERO-S) Study. Blood, 2016, 128, 251-251.	1.4	1
68	Untreated Bleeds May Be Historically Under-Reported and More Prevalent in People with Hemophilia A with Inhibitors: An Examination of Bleed Data from a Prospective, Non-Interventional Study. Blood, 2018, 132, 383-383.	1.4	1
69	Sars-Cov-2 Vaccination in Patients with Pre-Existing Immune Thrombocytopenia. Blood, 2021, 138, 586-586.	1.4	1
70	Development of factor IX inhibitor in an adult with severe haemophilia B following COVIDâ€19 vaccination: A case report. Haemophilia, 2022, 28, .	2.1	1
71	Immune thrombocytopenia in the elderly: immunosenescent and clinical diversity. British Journal of Haematology, 2022, 196, 1134-1136.	2.5	1
72	Von Willebrand Disease (VWD) - A Disease with Dual Factor Deficiencies- Discrepant FVIII:C Pharmacokinetic (PK) Characteristics in a Head to Head Trial of Two VWF/FVIII Concentrates.. Blood, 2007, 110, 2141-2141.	1.4	0

#	Article	IF	Citations
73	Treatment of Acute Bleeds in Acquired Hemophilia: Analysis from the Hemophilia Research Society (HRS) and Hemophilia and Thrombosis Research Society (HTRS) Registry.. Blood, 2008, 112, 2285-2285.	1.4	0
74	Treatment of Acute Bleeds in Acquired Hemophilia: An Updated Analysis From the Hemophilia and Thrombosis Research Society (HTRS) Registry.. Blood, 2009, 114, 3499-3499.	1.4	0
75	Economic Comparison Of Treating Hemophilia Patients Who Have Developed Inhibitors Via Immune Tolerance Induction Versus Prophylaxis and On-Demand Treatment With Bypassing Agents. Blood, 2013, 122, 422-422.	1.4	0
76	Relapsing Thrombotic Thrombocytopenic Purpura: A Single Center Experience. Blood, 2016, 128, 3732-3732.	1.4	0
77	Safety and Efficacy of Recombinant Factor XIII (FXIII) in Patients with Congenital FXIII A-Subunit Deficiency, Results from the Mentorâ„¢2 Trial. Blood, 2016, 128, 2573-2573.	1.4	0
78	Chronic Kidney Disease (CKD) in the U.S. Hemophilia Population: A Cohort Study. Blood, 2018, 132, 2479-2479.	1.4	0
79	Prospective, Phase III Study of the Efficacy, Safety, and Pharmacokinetics of a Human Antithrombin III Concentrate in Congenital Antithrombin Deficiency during Surgery or Childbirth. Blood, 2021, 138, 3238-3238.	1.4	0
80	Highlights in nonmalignant hematology from the 2019 American Society of Hematology meeting. Clinical Advances in Hematology and Oncology, 2020, 18, 86-88.	0.3	0